- Aptevo Therapeutics (APVO +1%) will launch an open-label proof-of-concept Phase 2 clinical trial this quarter evaluating monospecific antibody candidate otlertuzumab, combined with the chemo agent bendamustine, for the treatment of peripheral T-cell lymphoma (PTCL), a new indication. The primary endpoint of the 24-subject study will be response rate.
- Enrollment of patients with chronic lymphocytic leukemia (CLL) will be discontinued but the company says it will explore partnerships to support Phase 3 development in CLL.
- Otlertuzumab targets a B-cell surface protein called CD37 which is also present on the surface of T-cell lymphomas.
- Aptevo expects to file INDs in 2018 for two bispecific antibody candidates developed with its ADAPTIR platform: APVO436 for acute myeloid leukemia and APVO210 for autoimmune and inflammatory diseases.
- Now read: Acadia Pharmaceuticals: The Harmony Trial And Buyout Potential
Original article